Phase I Trial of Pyragrel, a Novel Thromboxane Synthetase Inhibitor, to Evaluate the Safety, Tolerability, and Pharmacokinetics in Healthy Volunteers

Background and Objective: Inhibition of thrombosis and platelet aggregation through a thromboxane synthetase inhibitor proved to be an effective and promising treatment for cardiovascular and/or cerebrovascular disease (CCVD) patients. This phase I study evaluated the safety, tolerability, and pharm...

Descripción completa

Detalles Bibliográficos
Autores principales: Zou, Chan, Zuo, Xiaocong, Huang, Jie, Hua, Ye, Yang, Shuang, Yang, Xiaoyan, Guo, Can, Tan, Hongyi, Chen, Jun, Chu, Zhaoxing, Pei, Qi, Yang, Guoping
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Frontiers Media S.A. 2019
Materias:
Pharmacology
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6821791/
https://www.ncbi.nlm.nih.gov/pubmed/31708774
http://dx.doi.org/10.3389/fphar.2019.01231

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6821791/
https://www.ncbi.nlm.nih.gov/pubmed/31708774
http://dx.doi.org/10.3389/fphar.2019.01231

Ejemplares similares